- Home
- IMVT vs GBDC Comparison
IMVT vs GBDC Comparison
Compare IMVT & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- GBDC
- Stock Information
- Founded
- IMVT N/A
- GBDC 2009
- Country
- IMVT United States
- GBDC United States
- Employees
- IMVT N/A
- GBDC N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- GBDC Finance: Consumer Services
- Sector
- IMVT Health Care
- GBDC Finance
- Exchange
- IMVT Nasdaq
- GBDC Nasdaq
- Market Cap
- IMVT 3.6B
- GBDC 4.0B
- IPO Year
- IMVT N/A
- GBDC 2010
- Fundamental
- Price
- IMVT $23.86
- GBDC $15.40
- Analyst Decision
- IMVT Strong Buy
- GBDC Buy
- Analyst Count
- IMVT 11
- GBDC 6
- Target Price
- IMVT $46.11
- GBDC $16.25
- AVG Volume (30 Days)
- IMVT 1.1M
- GBDC 1.2M
- Earning Date
- IMVT 02-10-2025
- GBDC 02-04-2025
- Dividend Yield
- IMVT N/A
- GBDC 10.13%
- EPS Growth
- IMVT N/A
- GBDC N/A
- EPS
- IMVT N/A
- GBDC 1.36
- Revenue
- IMVT N/A
- GBDC $724,677,000.00
- Revenue This Year
- IMVT N/A
- GBDC $23.90
- Revenue Next Year
- IMVT N/A
- GBDC N/A
- P/E Ratio
- IMVT N/A
- GBDC $11.32
- Revenue Growth
- IMVT N/A
- GBDC 20.16
- 52 Week Low
- IMVT $22.41
- GBDC $14.05
- 52 Week High
- IMVT $41.38
- GBDC $17.72
- Technical
- Relative Strength Index (RSI)
- IMVT 40.92
- GBDC 58.22
- Support Level
- IMVT $22.41
- GBDC $15.18
- Resistance Level
- IMVT $25.29
- GBDC $15.41
- Average True Range (ATR)
- IMVT 1.25
- GBDC 0.17
- MACD
- IMVT 0.03
- GBDC 0.04
- Stochastic Oscillator
- IMVT 42.90
- GBDC 96.77
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.